Inclusion Criteria:

1. Male or female patients >=18 years of age

2. the histological diagnosis of small cell lung cancer;

3. Patients who had first-line treatment failure or relapse after first-line therapy;

4. enough tumor tissue specimens for molecular marker analysis;

5. Measurable disease by RECIST criteria

6. ECOG performance status of <=2.

7. Life expectancy of at least 3 months.

8. Laboratory values as follows:: ANC ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; HB ≥
90g/L; serum bilirubin ≤ 1.5 upper limit of normal (N); ALT/AST≤ 2N (in patients with
liver metastases :ALT/AST≤ 5N) creatinine≤1.25 N;and clearance rate of creatinine ≥
60mLl/min; proteinuria < 2+, or were detected in 24 hour urine protein, protein
content is ≤1g

9. Patient must be accessible for treatment and follow-up

10. All patients must be able to understand the nature of the study and give written
informed consent prior to study entry

Exclusion Criteria:

1. mixed small cell lung cancer;

2. patients had a previous diagnosis of malignant tumor;

3. HIV infection;

4. A history of cardiac disease as defined by malignant hypertension, unstable angina,
congestive heart failure of > grade 2 per New York Heart Association (NYHA) criteria,
myocardial infarction within the previous 6 months, or symptomatic cardiac
arrhythmias.

5. patients had the motor or sensory neurons lesions/symptoms of NCI - CTC AE > 1;

6. patients had serious active infections;

7. patients were allergic to ifosfamide or liposomal doxorubicin